Uricostatics: Control of Uric Acid Synthesis
The primary representative of drugs affecting purine metabolism is allopurinol (Allopurinolum). Structurally, this compound is an exact structural analog of hypoxanthine. On exams and test questions, this fact is frequently tested: students must clearly differentiate hypoxanthine from other related molecules such as guanine, adenine, or xanthine. It is this structural similarity to hypoxanthine that allows allopurinol to successfully interfere with the body's natural biochemical cascades.
The main pharmacological target of allopurinol is the enzyme xanthine oxidase. Acting as a specific blocker of this enzyme, the drug purposefully disrupts the synthesis of uric acid. Because the formation of uric acid is halted, allopurinol is classified strictly as a uricostatic (from stasis — a standstill).
In clinical practice, it is crucial to understand allopurinol's place in the treatment regimen. Its primary and most important indication is baseline therapy. The drug is prescribed for the long-term prophylaxis of gout attacks. Students often make the grave mistake of assuming it is used in the acute phase: it must be firmly remembered that allopurinol is absolutely not used for the direct treatment and relief of pain during an acute gouty attack.
Uricosuric Agents: Enhancing Excretion
The second major group of drugs for gout control is uricosuric agents. A prominent representative of this pharmacological group is benzbromarone (Benzbromaronum).
Unlike uricostatics, benzbromarone does not interfere with enzyme function and does not stop uric acid synthesis. Its mechanism of action is realized at the level of the excretory system, specifically in the renal tubules. The drug specifically blocks the process of reabsorption (tubular reuptake) of uric acid. As a result of this physiological block, uric acid does not return to the systemic circulation, but is actively excreted from the body in the urine.
Interestingly, in complex clinical situations, the pharmacological properties of different groups can be beneficially combined. Combination therapy is permitted, wherein benzbromarone is used concurrently with allopurinol. This combination allows simultaneous action on two links of the pathogenesis: one drug inhibits the formation of the pathological agent, while the second accelerates the excretion of what has already been produced.
Differential Diagnosis and Common Pitfalls
When studying the pharmacology of gout medications, special attention is paid to the differential diagnosis of drugs and understanding their adverse effects. One of the most frequent misconceptions is related to diuretics.
It might seem logical that agents increasing urine output should promote uric acid excretion. However, classic diuretics such as furosemide (Furosemidum), hydrochlorothiazide (Hydrochlorothiazidum), and the osmotic diuretic mannitol (Mannitolum) do not belong to uricosuric agents. Moreover, their use often causes the exact opposite, undesirable effect — hyperuricemia (pathological elevation of blood uric acid concentration), which can trigger a severe gout flare.
Additionally, when differentiating drug groups, it is necessary to clearly distinguish their mechanisms and pharmacological classification. As previously mentioned, allopurinol is strictly a uricostatic. In test questions, it is frequently misidentified as a uricosuric agent, a COX inhibitor, or colchicine (Colchicinum). This is incorrect: allopurinol has no direct effect on tubular reabsorption in the kidneys and possesses entirely different sites of action compared to COX inhibitors and colchicine.